NOVEMBER 2015 ARTICLE LIST >>
PharmaTutor (November- 2015)
Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 3, Issue 11)
Received On: 13/05/2015; Accepted On: 03/07/2015; Published On: 01/11/2015
AUTHORS: Shalja Verma, Anand Kumar Pandey*
Department of Biotechnology, Institute of Engineering & Technology,
Bundelkhand University, Jhansi, Uttar Pradesh, India
vnsanand_9@rediffmail.com
ABSTRACT: Cancer is the second principal death cause, in the recent scenario 1 out of every 4 people die out of cancer. Not more than 50% advanced cancer subjects live a year ahead. RNA interference (RNAi) a phenomenon which serves for shutting off the expression of a specific sequence has proved itself a finest weapon against cancer. This mechanism involves silencing of the expression of desired mRNA sequence by degrading it using a dsRNA (double stranded RNA) molecule having complementarity to the desired mRNA. However a major challenge in proficient implementation of this therapy against cancer is lack of efficient delivery methods for the dsRNA to the target tissue. Various delivery methods had already been developed for efficient and effective delivery of the dsRNA and many are under trial. This review is going to present the great efficacy of RNAi against cancer and the various delivery methods performing capable work in accurate application of this therapy.
How to cite this article: S Verma, AK Pandey; RNA Interference-weapon against cancer; PharmaTutor; 2015; 3(11); 19-24
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Fire Andrew, Xu SiQun, Montgomery Mary K., Kostas Steven A., Driver Samuel E., Mello Craig C.; Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans; Nature; 1998; 391(6669); 806-811
2. Lee J.-M., Yoon T.-J. & Cho Y.-S.; Recent Developments in Nanoparticle-Based siRNA Delivery for Cancer Therapy; BioMed Research International ; 2013; 10
3. Elbashir S.M., Lendeckel W. & Tuschl T.; RNA interference is mediated by 21- and 22-nucleotide RNAs; Genes & Development; 2001; 15(2); 188-200
4. Rivera Díaz M. & Vivas-Mejia P.E.; Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes; Pharmaceutical; 2013; 6(11); 1361-1380
5. van Kouwenhove M., Kedde M. & Agami R.; MicroRNA regulation by RNA-binding proteins and its implications for cancer; Nat Rev Cancer; 2011; 11(9); 644-656
6. Iorio M.V. & Croce C.M.; MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review; EMBO Molecular Medicine; 2012; 4(3); 143-159
7. Bumcrot D., Manoharan M., Koteliansky V. & Sah D.W.Y.; RNAi therapeutics: a potential new class of pharmaceutical drugs; Nat Chem Biol; 2006; 2(12); 711-719
8. Jose Ernesto Belizário & Dayson Friaça Moreira; RNA Interference Against Human Cancers: a Perspective; Applied Cancer Research; 2009; 29(4); 157-161
9. Stevenson M.; Therapeutic Potential of RNA Interference; New England Journal of Medicine; 2004; 351(17); 1772-1777
10. Ozpolat B., Sood A.K. & Lopez-Berestein G; Liposomal siRNA nanocarriers for cancer therapy; Advanced Drug Delivery Reviews; 2014; 66(0); 110-116
11. Jong-Min Lee, Tae-Jong Yoon, and Young-Seok Cho; Recent Developments in Nanoparticle-Based siRNA Delivery for Cancer Therapy; Article ID 782041; 2013
12. Rivera Díaz M. & Vivas-Mejia P.E.; Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes; Pharmaceuticals; 6(11); 1361-1380
13. Minakuchi et al.; Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo; Nucleic Acids Research; 2004; 32(13); 109
14. Shen C., Buck A.K., Liu X., Winkler M. & Reske S.N.; Gene silencing by adenovirus-delivered siRNA; FEBS Letters; 2003; 539(1); 111-114
15. Soutschek et al.; Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs; Nature; 2004; 432(7014); 173-178
16. Dong et al.; Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates; Proceedings of the National Academy of Sciences; 2014; 111(11); 3955-3960
17. Mansoori B., Sandoghchian Shotorbani S. & Baradaran B; RNA Interference and its Role in Cancer Therapy; Advanced Pharmaceutical Bulletin; 2014; 4(4); 313-321
18. Jiang T., Mo R., Bellotti A., Zhou J. & Gu Z.; Gel–Liposome-Mediated Co-Delivery of Anticancer Membrane-Associated Proteins and Small-Molecule Drugs for Enhanced Therapeutic Efficacy; Advanced Functional Materials; 2014; 24(16); 2295-2304
19. Wu S.Y., Lopez-Berestein G., Calin G.A. & Sood A.K.; Targeting the undruggable: Advances and obstacles in current RNAi therapy; Science translational medicine; 2014; 6(240); 240ps7
20. Denise et al.; Deep Sequencing Insights in Therapeutic shRNA Processing and siRNA Target Cleavage Precision; Mol Ther Nucleic Acids; 2014; 3; e145
.png)
